A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics,
Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.